Pertuzumab

Records for this ingredient, by country (identity only).

ATC L01FD02 · 13 markets · 54 records

Pertuzumab 13 markets · 54 records Forms
Filters
Kind

ES 9 records · 4 shown of 4 Source CIMA (AEMPS) · Data as of live

Only this ingredient

  • 420 mg per mL / per unit basis not statedinjectionPERJETA

Combination products containing this ingredient

  • 1,200 mg per mL / per unit basis not statedinjection CombinationPertuzumab 1,200 mg + Trastuzumab 600 mgPhesgo
  • 600 mg per mL / per unit basis not statedinjection CombinationPertuzumab 600 mg + Trastuzumab 600 mgPhesgo
  • 1,200 mg per mL / per unit basis not statedinjection CombinationPertuzumab 1,200 mg + TrastuzumabPhesgo

AU 5 records · 4 shown of 4 Source TGA、PBS Schedule API v3 (Department of +1 · Data as of 2026-10-28、live · some records have no stated strength · includes records with unknown status (not proof of sale)

Only this ingredient

  • 420 mg per mL / per unit basis not statedinjectionPERJETA pertuzumab (rch) 30mg/mL concentrate injection vial unknown
  • 420 mg/14 mLinjectionPERJETA also in GB·JP

Combination products containing this ingredient

  • 1,200 mg per mL / per unit basis not statedinjection CombinationPertuzumab 1,200 mg + Trastuzumab 600 mg + Water For Injections 15 mLPHESGO SC pertuzumab (rch) 1200mg and trastuzumab (rch) 600mg in 15mL solution for injection, vials unknown
  • 600 mg per mL / per unit basis not statedinjection CombinationPertuzumab 600 mg + Trastuzumab 600 mg + Water For Injections 10 mLPHESGO SC pertuzumab (rch) 1200mg and trastuzumab (rch) 600mg in 15mL solution for injection, vials unknown
1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商

GB 4 records · 3 shown of 3 Source NHSBSA dm+d · Data as of 2026-10-19

Only this ingredient

Combination products containing this ingredient

CA 4 records · 4 shown of 4 Source Health Canada Drug Product Databas · Data as of 2026-10-23

Only this ingredient

Combination products containing this ingredient

  • 80 mg per mL / per unit basis not statedliquid CombinationPertuzumab 80 mg + Trastuzumab 40 mgPhesgo
  • 60 mg per mL / per unit basis not statedliquid CombinationPertuzumab 60 mg + Trastuzumab 60 mgPhesgo
  • 30 mg/1 mLliquid CombinationPertuzumab 30 mg/1 mL + Trastuzumab 440 mgPERJETA-HERCEPTIN

CN 4 records · 1 shown of 1 Source 国家医保局 医保药品分类与代码数据库 · Data as of 2025-04-04

Only this ingredient

  • 420 mg per mL / per unit basis not statedinjection安赛珠帕妥珠单抗帕乐坦、帕捷特

US 3 records · 3 shown of 3 Source openFDA NDC Directory · Data as of 2026-10-23

Only this ingredient

  • 30 mg per mL / per unit basis not statedinjectionPERJETA

Combination products containing this ingredient

  • 1,200 mg/15 mLinjection CombinationHyaluronidase (Human Recombinant) 30,000 unit/15 mL + Pertuzumab 1,200 mg/15 mL + Trastuzumab 600 mg/15 mLPhesgo
  • 600 mg/10 mLinjection CombinationHyaluronidase (Human Recombinant) 20,000 unit/10 mL + Pertuzumab 600 mg/10 mL + Trastuzumab 600 mg/10 mLPhesgo

SG 3 records · 3 shown of 3 Source Health Sciences Authority (HSA) · Data as of 2026-08-07

Only this ingredient

Combination products containing this ingredient

TW 3 records · 1 shown of 1 Source 衛生福利部食品藥物管理署(TFDA)全部藥品許可證資料集 · Data as of 2026-10-22 · some records have no stated strength

Only this ingredient

  • 420 mg per mL / per unit basis not statedinjectionPerjeta Vial 420mg賀疾妥注射液420毫克
2 records · 0 manufacturers 2 registros · 0 fabricantes 2 个记录 · 0 个厂家 2 個記錄 · 0 個廠商
With a brand name Con nombre comercial 有商品名 有商品名Phesgo Solution for Subcutaneous Injection 1200/600 mg ×8賀雙妥皮下注射劑 1200/600毫克 ×1賀雙妥皮下注射劑 600/600毫克 ×1

Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包

HK 3 records · 0 shown of 0 Source 衞生署藥物辦公室(香港)註冊藥劑製品名單 · Data as of 2026-10-23 · some records have no stated strength · includes records with unknown status (not proof of sale)

3 records · 0 manufacturers 3 registros · 0 fabricantes 3 个记录 · 0 个厂家 3 個記錄 · 0 個廠商
With a brand name Con nombre comercial 有商品名 有商品名PERJETA CONCENTRATE FOR SOLUTION FOR INFUSION 420MG/14ML ×2PHESGO SOLUTION FOR SUBCUTANEOUS INJECTION 1200MG/600MG IN 15ML ×4

Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包

JP 3 records · 3 shown of 3 Source 厚生労働省 薬価基準収載品目リスト · Data as of 2026-11-01

Only this ingredient

  • 420 mg/14 mLinjectionパージェタ点滴静注420mg/14mL also in AU·GB

Combination products containing this ingredient

  • 15 mL per mL / per unit basis not statedinjection CombinationBerahyaluronidase Alfa 15 mL + Pertuzumab 15 mL + Trastuzumab 15 mLフェスゴ配合皮下注 IN
  • 10 mL per mL / per unit basis not statedinjection CombinationBerahyaluronidase Alfa 10 mL + Pertuzumab 10 mL + Trastuzumab 10 mLフェスゴ配合皮下注 MA

EU 3 records · 0 shown of 0 Source European Commission · Data as of 2026-11-03 · some records have no stated strength

EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.

3 records · 0 manufacturers 3 registros · 0 fabricantes 3 个记录 · 0 个厂家 3 個記錄 · 0 個廠商
With a brand name Con nombre comercial 有商品名 有商品名PERJETA ×2Phesgo ×2POHERDY ×2

Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包

FR 3 records · 3 shown of 3 Source Base de données publique des médic · Data as of 2026-11-03

Only this ingredient

  • 30 mg/1 mLinjectionPERJETA 420 mg, solution à diluer pour perfusion

Combination products containing this ingredient

MX 1 records · 0 shown of 0 Source COFEPRIS · Data as of annual · some records have no stated strength

1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商

Some strengths are recorded without a per mL / per unit basis. They are shown as recorded and are not compared with other markets.

The same ingredient can carry completely different brand names in different countries, and the same name can point to a different ingredient. Listed by country — not interchangeable.

Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.

A side-by-side table is offered only when this ingredient has records in many markets; otherwise this list is the whole picture.